On Thursday, shares of Jubilant Life Sciences zoomed 6.7 per cent accompanied by extraordinary volumes. This rise was triggered by the 18 per cent price increase of its vitamin tablet, Niacin. . With this rally, the stock emphatically broke out of a sideways consolidation that was in place from early December 2013, in the range of ₹110-145. This rally provides a buying opportunity for traders with a short-term perspective. The intermediate- and short-term trends are up for the stock. It is hovering well above its 50- and 200-day moving averages. The relative strength index on the daily chart has re-entered the bullish zone from the neutral region.

The short-term outlook for Jubilant Life is bullish. It can extend its rally and reach the price target of ₹157.5 and then ₹161 in the approaching trading sessions. Buy the stock with a stop-loss at ₹147.8 level.

(Note: The recommendations are based on technical analysis. There is a risk of loss in trading.)

(This article was published on March 13, 2014)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.